|
|
Emerging Therapies to Treat Lupus ErythematosusPublished by: Decision Resources Published: Sep. 21, 2006 - 23 Pages Price reduced due to age.Table of Contents
AbstractLupus erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptoms-and there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication.Get the Answers You Need to Shape Your Strategy The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrollment for clinical trials can be diffi cult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges? Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a signifi cant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current fi rst-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater effi cacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies' modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||